Good news after good news for Biocartis

October 19, 2016 News BioVox

After the Idylla test for lung cancer was recognized as best-in-class in a recent study, Biocartis also receives a € 2.5 million grant from the Flemish government.

In a study comparing lung-cancer detection assays, Biocartis’ test came out as best-in-class. The study, carried out by pharma giant AstraZeneca, compared 12 technologies detecting the KRAS-mutation, the most common driver of non-small-cell lung cancer (NSCLC). The Idylla™ KRAS test belonged to the group of most sensitive tests but completely wiped out the competition in terms of ease-of-use and time-to-result. While the Biocartis test provided results in 2 to 4 hours, alternative methods took 1 day to 3 weeks to complete. The recently published study confirms the status of Idylla™ tests as sensitive, easy to use and lightning fast.

“We are extremely proud with the results of this study organized by a leading global pharmaceutical company like AstraZeneca,” responds CEO Rudi Pauwels. “This is the broadest comparison study conducted by an external party on Idylla™ performance to date with respect to the number of different technologies applied on one sample set. It demonstrates that with the Idylla™ technology, we can truly combine the advantages of point-of-care testing in terms of ease-of-use and speed with the performance that one would expect from technologies used in reference laboratories. As such, the Idylla™ technology has the potential to make rapid molecular diagnostic testing available in any routine diagnostic lab setting – large or small.”

Investors responded enthusiastically to the news and propelled the company’s stock price 20% higher.

And that wasn’t even all of the good news. The Flemish government announced that it would support Biocartis with a € 2.5 million grant. Biocartis will use the funds for the expansion of their manufacturing capacity. At the moment, Biocartis produces 200.000 to 250.000 Idylla™ tests each year. The new production line, expected to be operational in 2017, will crank up production to 1 million tests produced annually. The investment will also create about 100 jobs in the coming 5 years.

More news on Biocartis here


BioVox
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts